Skip to content
Merck Sharp & Dohme (MSD)
-
MSD licenses KRAS G12D drug from China’s SciBrunch in US$2.13B oncology deal
The deal comes as pharmaceutical companies increase investment in therapies that target RAS, a family of proteins involved in regulating cell growth and division.
-
Merck advances EyeBio’s Remigromig in US trial for diabetic macular edema
Merck plans to present the BRUNELLO results at the American Academy of Ophthalmology Annual Meeting in New Orleans on October 10 and discuss the findings with regulatory authorities.
-
MSD convenes high-level UHC policy roundtable with Africa Health Business in Accra
The meeting brings together stakeholders to discuss practical approaches to strengthening Ghana’s health system and advancing national UHC priorities.
-
Aspen secures African rights to MSD’s once-monthly HIV prevention pill
The agreement covers 129 countries, including all African nations, and gives Aspen rights across both public and private healthcare sectors.